• INCINTAS THERAPEUTICS, INC.

    Optimized Uterine Genomics

    for Improved Pregnancy Outcome

    in Assisted Reproduction

  • Improved Bioavailability

    via Targeted Delivery

    Novel Route of Administration

     

    Refined Uterine Preparation in IVF to Maximize Uterine Gene Expression and Embryonic Implantation

    About Us

    WHAT WE DO

    (We intend to move the needle pretty far in IVF)

    We are an accomplished team of scientists, physicians and business professionals who are focused upon improving pregnancy outcome in reproductive medicine.

    Our sole purpose is to resolve the problem of failed embryonic implantation (the main hurdle in achieving pregnancy in IVF) to ultimately encourage Single Embryo Transfer (SET) which is more likely to result in a healthy singleton pregnancy for the infertile couple.

    The efficacy of a drug is determined by how and where it is administered in the human body.

    For over 40 years, since the success of the first test tube baby, doctors have been administering progesterone to the outside of the uterus via IM injection and vaginal suppositories. Unfortunately, these conventional methods moreoften fail to provide the proper range of progesterone sufficiently long enough for the complex gene expression within the lining of the uterus which establishes the "Window of Implantation". Just as in healthy pregnancy, the WOI is the only time a woman can achieve pregnancy and must be artificially re-created with progesterone in order for the IVF cycle to be successful.

     

    Recent human genomic data demonstrates how we've been artificially re-creating a receptive uterus for only 32 hrs. (maximum) in all IVF cycles for over four decades.

     

    Incintas Therapeutics resolved this problem by administering progesterone to the inside of the uterus using a controlled-release formulation of progesterone which provides optimal molecular bioavailability for up to 96 hrs. The sustained "proper" concentration results in prolonged endometrial gene expression and a lengthened WOI, which increases the likelihood of implantation for the embryo in the process. Human clinical data has demonstrated fertility outcome of 81.5% when endometrial gene expression is complete, ("receptive" genomic state of ER Map Technology findings, n=200+).

     

    Incintas' liquid hormonal therapeutic is administered by the clinician prior to anticipated embryo transfer via standard IVF protocol using an ultrasound guided ET catheter, to ideally prime the endometrial lining for implantation and establishment of pregnancy.

     

    Incintas' novel intrauterine route of progesterone administration sustains endometrial biomarker expression up to three times longer than all conventional uterine preparation methods by having the hormone administered where it needs to be....inside the uterus, not the bloodstream.

     

    Plus , we patented the targeted drug delivery methods and formulation capabilities in the US and Europe with global rights pending.

     

     

     

    Partnering Advantages

    -Early to Mid Stage Entry

    -Sound Preclinical Genomic Data (Human)

    -Large Existing Market Potential (2M IVF Cycles/yr Globally)

    -Growing Market in Women's Healthcare

    -Established Intellectual Property

    -Seasoned Business Partners

    -Supported by Prominent IVF Luminaries

    from around the World

    -Expedited Regulatory Agenda to Commercialization

    -Formulations Established with Proprietary Nanoformulation Protection (Patented, US)

    -Life Saving/Life Changing Technology

    -Rapid Scaling due to Inferior Competition in a 'Desparate' field of Medicine

     

     

     

     

     

     

    .

    Preclinical Data (Proprietary)

    The precise hormonal range whereby progesterone becomes a pregnancy promoter to the upper limit which identifies the contraceptive effect (eg: IUD/the Pill) has been identified for the first time in medical history.

    This ideal hormonal range defines the Incintas advantage for our controlled-release capabilities.

     

     

     

     

     

    .

  • Executive Partners

    On a mission to help millions of fertility challenged families

    Jesse Pizolato

    CEO

    Founding Partner

    Michael Barton

    CFO

    Founding Partner

    Harald F. Stock, PhD

    Strategic Advisor

    Business Development

    Kun Zoo Kim, MD

    Founding Partner

  • Scientific Partners

    The Experts Behind Incintas Therapeutics' Breakthrough Technology

    Carlo Bulletti, MD, CSO

    IVF Luminary

    Dr. Carlo Bulletti is Director of the Physiopathology Unit of Reproduction at Rimini General Hospital, University of Bologna, Italy. He has authored 10 medical text books, 130 medical book chapters and more than 160 scientific articles.

    (www.carlobulletti.com)

    Robert Taylor,

    MD, PhD, CMO

    Endometriosis Luminary

    Robert N. Taylor, MD PhD is
    Professor, Reproductive Endocrinology and Infertility
    University of Utah Health
    Obstetrics & Gynecology Research Network
    30 North 1900 East, Suite 2A242
    Salt Lake City, Utah USA 84132

    Santiago Munne, PhD

    HoMu Investis

    Jose Horcajadas, PhD

    HoMu Investis

  • Graphical Analysis

    IM and PV endometrial concentrations (human biopsy data)

    ..........vs. the Incintas Advantage

    Progesterone Concentration vs. Time

    Genomic Data now confirms Endometrial Biopsy Data as depicted in a 1-1/3 day bioavailability of the proper hormonal concentration in order to achieve implantation of the embryo

  • In Memory Of

     

     

    Mitchell V. Pizolato,

    Nov. 23 -Nov. 29, 2000.

    Multiple IVF Birth

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Lance D. Pizolato

    Nov. 23 - Dec. 1, 2000

    Multiple IVF Birth

    Rest in Peace, my dear sons.